Personalis Inc. logo

Personalis Inc. (PSNL)

Market Open
20 Jul, 16:15
NASDAQ (NMS) NASDAQ (NMS)
$
13. 40
-1.99
-12.898%
$
1.47B Market Cap
- P/E Ratio
- Div Yield
7.69M Volume
-2.21 Eps
$ 15.39
Previous Close
Analysts:
Add Transaction
Day Range
13.11 14.75
Year Range
3.84 16.39
Want to track PSNL and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Personalis (PSNL) Upgraded to Buy: Here's Why

Personalis (PSNL) Upgraded to Buy: Here's Why

Personalis (PSNL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks | 1 year ago
Personalis price target raised to $9 from $7 at Lake Street

Personalis price target raised to $9 from $7 at Lake Street

Lake Street raised the firm's price target on Personalis to $9 from $7 and keeps a Buy rating on the shares after the company reported preliminary Q4 revenue ahead the firm's estimate and consensus. With cash to breakeven, a strong commercial partner, "robust" clinical data, and the potential for multiple reimbursement approvals, the firm views 2025 as "another transformative year" for Personalis, the analyst tells investors.

Thefly | 1 year ago
Personalis, Inc. (PSNL) Q3 2024 Earnings Call Transcript

Personalis, Inc. (PSNL) Q3 2024 Earnings Call Transcript

Personalis, Inc. (PSNL) Q3 2024 Earnings Call Transcript

Seekingalpha | 1 year ago
Personalis (PSNL) Reports Q3 Loss, Tops Revenue Estimates

Personalis (PSNL) Reports Q3 Loss, Tops Revenue Estimates

Personalis (PSNL) came out with a quarterly loss of $0.64 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $0.51 per share a year ago.

Zacks | 1 year ago
Personalis: Resetting My Strategy Following The Q2 Beat

Personalis: Resetting My Strategy Following The Q2 Beat

PSNL stock has surged from $1.61 to over $4.00 per share following strong Q2 earnings and increased demand for NeXT Personal MRD test. Personalis reported $22.6M in revenue for Q2, with improved gross margins and increased full-year revenue guidance. Personalis secured Medicare coverage, expanded commercial partnerships, showcased product benefits, settled an IP lawsuit, and strengthened market position.

Seekingalpha | 1 year ago
Personalis, Inc. (PSNL) Hit a 52 Week High, Can the Run Continue?

Personalis, Inc. (PSNL) Hit a 52 Week High, Can the Run Continue?

Personalis (PSNL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks | 1 year ago
Personalis, Inc. (PSNL) Q2 2024 Earnings Call Transcript

Personalis, Inc. (PSNL) Q2 2024 Earnings Call Transcript

Personalis, Inc. (NASDAQ:PSNL ) Q2 2024 Earnings Conference Call August 7, 2024 5:00 PM ET Company Participants Caroline Corner - IR Chris Hall - CEO and President Aaron Tachibana - CFO and COO Rich Chen - CMO and EVP, R&D Conference Call Participants Madison Pasterchick - Morgan Stanley Vidyun Bais - BTIG Thomas Flaten - Lake Street Arthur He - H.C. Wainwright Operator Good day and welcome to the Personalis Second Quarter 2024 Earnings Conference Call.

Seekingalpha | 1 year ago
Personalis (PSNL) Reports Q2 Loss, Tops Revenue Estimates

Personalis (PSNL) Reports Q2 Loss, Tops Revenue Estimates

Personalis (PSNL) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.50 per share a year ago.

Zacks | 1 year ago